To achieve the objective of making available safe and efficacious medicinal products intended to treat or prevent COVID-19, a range of measures have been taken at Union level by the European Medicines Agency (EMA) and by the network of national competent authorities to facilitate, support and speed up the development and marketing authorisation of treatments and vaccines.
Recital 14, Regulation (EU) 2020/1043
In forcesince 15 Jul 2020cited 1×
Opinion of Advocate General Medina delivered on 15 September 2022. Union fédérale des consommateurs - Que choisir (UFC - Que choisir) and CoDecision
In that regard, it follows from Article 17 of Directive 2015/2302 that the organiser’s obligation to provide security for the refund of any payments made covers the situation where the relevant services are not performed as a consequence …
15 Sep 2022 · 62021CC0407